BioMarin Provides Updates on Progress in Gene Therapy Programs

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development. In February...

Related Keywords

Hank Fuchs ,Debra Charlesworth ,Traci Mccarty ,Worldwide Research ,Exchange Commission ,Prnewswire Biomarin Pharmaceutical Inc ,European Commission ,Drug Administration ,Biomarin Pharmaceutical Inc ,Nasdaq ,Marin Pharmaceutical ,Orphan Disease Designation ,Biomarin Pharmaceutical ,